期刊文献+

依维莫司加压毛细管电色谱含量测定方法建立

Establishment of content analysis method of everolimus by p CEC
下载PDF
导出
摘要 目的 采用反相加压毛细管电色谱法定量测定依维莫司含量.方法 使用反相色谱柱,以pH5.5的2mmol/L磷酸缓冲液(Na2HPO4-NaH2PO4)-乙腈(30∶70,V/V)为流动相,检测波长为278nm、分离电压为-16kV、流速为0.08mL/min,柱温49℃,等度洗脱.结果 经方法学考察确定最佳条件,在该条件下,依维莫司浓度在0.3~5.0mg/mL范围内线性良好(R2=0.9992,n=6);检出限(S/N=3)和定量限(S/N=10)分别为3.9和7.8 μg/mL;日间和日内精密度均小于5%;加样回收率均高于98%.结论 该方法简单方便、准确、灵敏、可靠,适用于依维莫司的定量分析.
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2015年第5期396-400,共5页 Chinese Journal of Antibiotics
基金 国家重大科学仪器设备开发专项(No.2011YQ15007208) 国家"重大新药创新"科技重大专项(No.2012ZX09301002-003) "十二五"大平台子课题(X-2-3)
  • 相关文献

参考文献8

二级参考文献132

  • 1李晓玉.免疫抑制剂的研究概述[J].药学服务与研究,2005,5(2):105-110. 被引量:19
  • 2Papadimitrakopoulou V,Soria J,Douillard J,et al.A phaseⅡstudy ofRAD001(R)(everolimus)monotherapy in patients(pts)with ad-vanced non-small cell lung cancer(NSCLC)failing prior platinum-based chemotherapy(C)or prior C and EGFR inhibitors(EGFR-I)[J].Journal of Clinical Oncology,2007,25:7589.
  • 3Ruirong Yuan,Andrea Kay,William Berg,et al.Targeting tumorigene-sis:development and use of mTOR inhibitors in cancer therapy[J].Journal of Hematology&Oncology,2009,2:45-56.
  • 4Soria J,Shepherd FA,Douillard JW,et al.Efficacy of everolimus(RAD001)in patients with advanced NSCLC previously treated withchemotherapy alone or with chemotherapy and EGFR inhibitors[J].An-nals of Oncology,2009,20(10):1674-1681.
  • 5Kay A,Motzer R,Figlin R,et al.Updated data from a phaseⅢrandom-ized trial of everolimus(RAD001)versus PBO in metastatic renal cellcarcinoma(mRCC)[R].American Society of Clinical Oncology Geni-tourinary Cancers Symposium,2009:278.
  • 6Weigelt B,Warne P,Downward J.PIK3CA mutation,but not PTEN lossof function,determines the sensitivity of breast cancer cells to mTORinhibitory drugs[J].Oncogene,2011,30:3222-3233.
  • 7Morassa,Mohseni,Benho.PIK3CA and KRAS mutations predict for re-sponse to everolimus therapy:now that's RAD001[J].The Journal ofClinical Investigation,2010,120(8):2655-2658.
  • 8Guy Jerusalem,Angelica Fasolo,Veronique Dieras,et al.PhaseⅠtrialof oral mTOR inhibitor everolimus in combination with trastuzumab andvinorelbine in pre-treated patients with HER2-overexpressing metastat-ic breast cancer[J].Breast Cancer Research and Treatment,2010,125:2447-2455.
  • 9Ahmad Awada,Fatima Cardoso,Christel Fontaine,et al.The oral mTORinhibitor RAD001(everolimus)in combination with letrozole in patientswith advanced breast cancer:Results of a phase I study with pharma-cokinetics[J].Original Research Article European Journal of Cancer,2008,44(1):84-91.
  • 10Susan Ellard,Mark Clemons.Randomized phaseⅡstudy comparing twoschedules of everolimus in patients with Recurrent/metastatic breastcancer:NCIC clinical trials group[J].American Society of Clinical On-cology,2009,27:4536-4541.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部